pre-seed
Stage
1
Investors
About
CaLycia Bioscience develops engineered, autologous macrophage cell therapies delivered directly into the central nervous system to target and treat aggressive brain tumors such as glioblastoma and brain metastases by phagocytosing tumor cells and stimulating adaptive immunity.
Explore CaLycia Bioscience's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.